Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: Results of the ENCORE 2 study

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1427-1433

  Else, Laura J ^a,b   Jackson, Akil ^c   Puls, Rebekah ^d   Hill, Andrew ^a   Fahey, Paul ^d   Lin, Enmoore ^d   Amara, Alieu ^b   Siccardi, Marco ^a   Watson, Victoria ^a,b   Tjia, John ^a   Emery, Sean ^d   Khoo, Saye ^a   Back, David J ^a   Boffito, Marta ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LAMIVUDINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTIDINE TRIPHOSPHATE; DIDEOXYNUCLEOTIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84857183342     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05599-11     Document Type: Article

References (28)

1. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168. (Pubitemid 37338889)
2. Anderson PL, et al. 2011. The cellular pharamcology of zidovudine and lamivudine according to HIV-status and gender, abstr. O-6. Abstr. 12th Int Workshop Clin. Pharmacol. HIV Ther.
3. Anderson PL, et al. 2007. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 21:1849-1854. (Pubitemid 47329761)
4. Bartlett JA, et al. 1996. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:161-172. (Pubitemid 126449258)
5. Cammack N, et al. 1992. Cellular metabolism of (-) enantiomeric 2′- deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
6. DeJesus E, et al. 2004. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin. Infect. Dis. 39:411-418. (Pubitemid 39050491)
7. Eron JJ, et al. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669. (Pubitemid 26002168)
8. Fletcher CV, et al. 2000. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14:2137-2144.
9. Flynn PM, et al. 2007. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob. Agents Chemother. 51:3516-3522. (Pubitemid 47519338)
10. Fromentin E, Gavegnano C, Obikhod A, Schinazi RF. 2010. Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. Anal. Chem. 82:1982-1989.
11. Harris M, et al. 2002. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 16:1196-1197. (Pubitemid 34533866)
12. Hart GJ, et al. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′- triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694.
13. Hawkins T, et al. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411. (Pubitemid 41003784)
14. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66. (Pubitemid 29056000)
15. Kewn S, Veal GJ, Hoggard PG, Barry MG, Back DJ. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595. (Pubitemid 27404693)
16. King T, et al. 2006. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 843:147-156. (Pubitemid 44636410)
17. Moore JD, et al. 2007. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir. Ther. 12:981-986. (Pubitemid 47492569)
18. Moore KH, et al. 1999. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250. (Pubitemid 29531443)
19. Moore KH, et al. 1999. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. 39:593-605. (Pubitemid 30629039)
20. Moore KH, et al. 1999. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob. Agents Chemother. 43:3025-3029.
21. Pruvost A, et al. 2009. Pilot pharmacokinetic study of human immuno-deficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob. Agents Chemother. 53:1937-1943.
22. Pruvost A, Theodoro F, Agrofoglio L, Negredo E, Benech H. 2008. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. J. Mass Spectrom. 43:224-233. (Pubitemid 351303443)
23. Robbins BL, Poston PA, Neal EF, Slaughter C, Rodman JH. 2007. Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine, and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 850:310-317. (Pubitemid 46618187)
24. Shi G, et al. 2002. Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:1092-1099. (Pubitemid 34555912)
25. Stretcher BN, Pesce AJ, Frame PT, Stein DS. 1994. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-1547. (Pubitemid 24203566)
26. U. S. Department of Health and Human Services. Last accessed 6 October 2011. Epivir 300 mg tablets UPI. U.S. Department of Health and Human Services, Washington, DC. http://www.accessdata.fda.gov /drugsatfda-docs/label/2008/ 020564s028lbl.pdf.
27. van Leeuwen R, et al. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1166-1171.
28. Yuen GJ, et al. 2004. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob. Agents Chemother. 48:176-182. (Pubitemid 38040195)